Literature DB >> 10880379

Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

E Heinmöller1, W Dietmaier, H Zirngibl, P Heinmöller, W Scaringe, K W Jauch, F Hofstädter, J Rüschoff.   

Abstract

Little or no data exist concerning the inactivation of tumor suppressor genes in intraductal lesions surrounding invasive ductal pancreatic carcinomas. Using a novel improved primer extension and preamplification polymerase chain reaction, we analyzed microdissected paraffin-embedded specimens of pancreatic carcinoma (n = 29) and their corresponding pancreatic intraductal lesions (PIL, n = 331) for loss of heterozygosity (LOH) of p16(INK4), DPC4, and p53 by microsatellite analysis and for p53 protein by immunohistochemistry. LOH at the p16(INK4) locus (9p21) was found in nine of 22 informative tumors (41%), in 15 of 25 tumors (60%) at the DPC4 locus (18q21.1), and in 22 of 27 tumors (81%) at the p53 locus (17p13). Homozygous deletions of p16(INK4) and DPC4 were found in eight of 22 (36%) and four of 25 tumors (16%), respectively. Furthermore, 24 of 29 tumors (83%) revealed considerable intratumoral genetic heterogeneity. In 165 of 277 PILs (60%) having suitable DNA for microsatellite analysis, alterations in at least one tumor suppressor gene were found. In individual PILs, up to three alterations were detected, and p53 LOH occurred even in morphologically normal-appearing ductal epithelium near the tumor. Although deletions of all three tumor suppressor genes were found in PILs without nuclear atypia, there was a tendency toward earlier LOH of p16(INK4) compared to DPC4 and p53 in these lesions. LOH in tumors accompanied positive p53 immunohistochemistry in 81% but only in 38% in PILs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880379      PMCID: PMC1850206          DOI: 10.1016/S0002-9440(10)64520-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Whole genome amplification from a single cell: implications for genetic analysis.

Authors:  L Zhang; X Cui; K Schmitt; R Hubert; W Navidi; N Arnheim
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.

Authors:  E E Schmidt; K Ichimura; H M Goike; A Moshref; L Liu; V P Collins
Journal:  J Neuropathol Exp Neurol       Date:  1999-11       Impact factor: 3.685

5.  Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid.

Authors:  F M van den Berg; I O Baas; M M Polak; G J Offerhaus
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

6.  Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation.

Authors:  A Yanagisawa; K Ohtake; K Ohashi; M Hori; T Kitagawa; H Sugano; Y Kato
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

7.  Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

Authors:  A B Lowenfels; P Maisonneuve; G Cavallini; R W Ammann; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

8.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.

Authors:  I O Baas; J W Mulder; G J Offerhaus; B Vogelstein; S R Hamilton
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

9.  Ki-ras oncogene activation in preinvasive pancreatic cancer.

Authors:  N R Lemoine; S Jain; C M Hughes; S L Staddon; B Maillet; P A Hall; G Klöppel
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

10.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.

Authors:  C Caldas; S A Hahn; R H Hruban; M S Redston; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

View more
  23 in total

1.  Inherited predisposition to pancreatic cancer.

Authors:  E Efthimiou; T Crnogorac-Jurcevic; N R Lemoine; T A Brentnall
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

2.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 3.  Cells of origin of pancreatic neoplasms.

Authors:  Junpei Yamaguchi; Yukihiro Yokoyama; Toshio Kokuryo; Tomoki Ebata; Masato Nagino
Journal:  Surg Today       Date:  2017-03-04       Impact factor: 2.549

4.  High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.

Authors:  Aimee L Lucas; Reena Shakya; Marla D Lipsyc; Elana B Mitchel; Sheila Kumar; Caroline Hwang; Liyong Deng; Catherine Devoe; John A Chabot; Matthias Szabolcs; Thomas Ludwig; Wendy K Chung; Harold Frucht
Journal:  Clin Cancer Res       Date:  2013-05-08       Impact factor: 12.531

5.  Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.

Authors:  Matthias Löhr; Günter Klöppel; Patrick Maisonneuve; Albert B Lowenfels; Jutta Lüttges
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

Review 6.  Beyond laser microdissection technology: follow the yellow brick road for cancer research.

Authors:  Luc G Legres; Anne Janin; Christophe Masselon; Philippe Bertheau
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

7.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Authors:  Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

8.  Update on pancreatic intraepithelial neoplasia.

Authors:  Ralph H Hruban; Anirban Maitra; Michael Goggins
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 9.  The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.

Authors:  Günter Klöppel; Jutta Lüttges
Journal:  Curr Gastroenterol Rep       Date:  2004-04

Review 10.  Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-01       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.